Generic API Manufacturing and Strategic API Development

One-stop solution for your deuterated APIs.

Generic API manufacturing brings an established active ingredient from route assessment through controlled, scalable manufacture. Clearsynth also advances strategic API development programs that require molecule-specific process, analytical and CMC planning.

Integrated API programs

From route selection to commercial API supply

Clearsynth supports generic and strategic programs with patent-aware route assessment, process development, analytical control, scale-up, technology transfer and customer regulatory-document support. Each work plan is built around the molecule, intended market, development stage, target scale and quality requirements.

225 kLReactor Volume

Manufacturing infrastructure supports scale progression when the selected chemistry, safety assessment, equipment fit and program requirements are aligned.

Technical capabilities

API process development built around control and scalability

The program team connects synthetic chemistry, solid-state understanding, analytical science, process safety and CMC execution so that decisions made early remain useful during API scale-up and transfer.

Route and supply assessment

Molecule, market and patent-aware route assessment; route scouting; scalable synthetic-route selection; and starting-material and supply-chain planning.

Process optimization

QbD-oriented process development covering yield, solvent use, waste, process economics and responsible-chemistry improvements.

Impurity control

Impurity mapping, fate-and-purge assessment and control strategies for process impurities, including potential genotoxic impurities.

Solid-form control

Crystallization, salt, polymorph, particle-property and solid-form studies aligned with isolation, handling and downstream needs.

Analytical and stability support

Analytical method development, qualification, phase-appropriate stability work and testing that supports release decisions.

Scale-up and CMC readiness

Process safety, scale-up, validation readiness, technology transfer, CMC support and customer regulatory-document support through supply.

Portfolio classification

Generic-market APIs and strategic development programs

The classification below separates Clearsynth's generic-market API work from its strategic API development portfolio. Program availability and status are assessed for each enquiry and jurisdiction.

Generic-market APIs

Programs evaluated for generic-market requirements, including route, quality, scale and documentation needs.

Strategic API development portfolio

API development opportunities advanced according to customer objectives, technical feasibility and applicable constraints.

Program stages

Support matched to the maturity of the API program

Development

Route scouting, proof of concept, process optimization, impurity understanding, analytical methods and initial solid-form decisions establish a scalable control strategy.

Validation-ready

Defined operating ranges, process-safety evidence, qualified methods, stability planning, starting-material controls and transfer documentation prepare the process for validation planning.

Commercial supply

Technology transfer, manufacturing execution, release support, change coordination, supply planning and ongoing process oversight support continuity at the agreed scale.

Connected expertise

Bring the right specialists into the program

API teams can connect with Clearsynth capabilities in analytical science, standards, custom synthesis and stable isotopes as the technical package develops.

Explore analytical capabilities View standards and research chemicals Discuss custom synthesis Explore stable-isotope services See deuterium-focused development

Technical FAQ

Generic API manufacturing questions

What qualifies as a generic API?

A generic API is an active pharmaceutical ingredient intended for a generic-drug program and developed to meet the applicable identity, quality, process-control, documentation and market requirements. Suitability is evaluated for the specific molecule and jurisdiction.

How is the Clearsynth API portfolio classified?

Deutetrabenazine, Lisdexamfetamine Dimesylate and Methylphenidate HCl are presented as generic-market APIs. Deucravacitinib, Deuruxolitinib, Deutivacaftor, Donafenib, Nor-S-Ketamine, Ruxolitinib Phosphate and Elacestrant are presented as the strategic API development portfolio.

Which API development stages are supported?

Clearsynth supports development, validation-ready preparation and commercial-supply work. The scope can include route scouting, process and analytical development, scale-up, transfer, release support, CMC activities and supply coordination.

How are impurities and solid form controlled?

Programs can combine impurity mapping, fate-and-purge assessment and genotoxic-impurity controls with crystallization, salt, polymorph, particle-property and solid-form studies. Controls are selected from molecule- and process-specific evidence.

What regulatory support is available?

Support can include phase-appropriate CMC content, analytical and stability summaries, process descriptions, control-strategy information and customer regulatory-document inputs. The exact package is agreed for the intended market and program stage.

What should an API manufacturing enquiry include?

Provide the molecule, program stage, intended market, target scale, known route or starting-material information, analytical requirements, documentation needs and timeline. Available process, impurity, solid-form and safety information also helps define the assessment.

Reviewed by Clearsynth Technical Team · Updated August 2026

Discuss your API program

Share the molecule, program stage, intended market, target scale, analytical and documentation requirements, and timeline so the technical team can route your enquiry.

Start a generic API enquiry